Larry A Harshyne
Overview
Explore the profile of Larry A Harshyne including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
533
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mastrolonardo E, Nunes K, Llerena P, Nikitina A, Sobol A, Scott E, et al.
Clin Cancer Res
. 2024 Nov;
31(3):515-528.
PMID: 39585339
Purpose: We evaluated whether indoleamine 2,3-dioxygenase (IDO1) inhibitor (IDOi) BMS986205 + PD-1 inhibitor nivolumab enhanced T-cell activity and augmented immune-mediated antitumor responses in untreated, resectable head and neck squamous cell...
2.
Bhattacharya P, Linnenbach A, South A, Martinez-Outschoorn U, Curry J, Johnson J, et al.
bioRxiv
. 2024 Oct;
PMID: 39386511
Immune checkpoint inhibition (ICI) has emerged as a critical treatment strategy for squamous cell carcinoma of the head and neck (HNSCC) that halts the immune escape of the tumor cells....
3.
Estephan L, Kumar G, Stewart M, Banoub R, Linnenbach A, Harshyne L, et al.
Front Oncol
. 2024 Jul;
14:1412212.
PMID: 38957320
Introduction: Oral cavity squamous cell carcinoma (OSCC) occurs most frequently in patients >60 years old with a history of tobacco and alcohol use. Epidemiological studies describe increased incidence of OSCC...
4.
Alnemri A, Tekumalla S, Moroco A, Vathiotis I, Tuluc M, Gargano S, et al.
Cancer Med
. 2024 Jun;
13(11):e7370.
PMID: 38847087
Objectives: Certain low-level immune-related adverse events (irAEs) have been associated with survival benefits in patients with various solid tumors on immune checkpoint inhibitors (ICIs). We aimed to investigate the association...
5.
Johnson J, Vathiotis I, Harshyne L, Ali A, Bar Ad V, Axelrod R, et al.
J Immunother Cancer
. 2023 Aug;
11(8).
PMID: 37536941
Background: The combination of nivolumab and ipilimumab has been approved for the treatment of multiple solid tumors. This was a phase I study investigating definitive radioimmunotherapy (RIT) with nivolumab and...
6.
Hill B, Calder A, Flemming J, Guo Y, Gilmore S, Trofa M, et al.
Mol Carcinog
. 2023 Jul;
62(9):1428-1443.
PMID: 37401875
Therapy using anti-PD-1 immune checkpoint inhibitors (ICI) has revolutionized the treatment of many cancers including head and neck squamous cell carcinomas (HNSCC), but only a fraction of patients respond. To...
7.
Herbst C, Harshyne L, Igyarto B
Front Immunol
. 2022 Nov;
13:1053582.
PMID: 36389660
Dendritic cells (DCs) are required for the initiation of the adaptive immune response. Their ability to acquire antigens in the periphery is a critical step in this process. DCs express...
8.
Luginbuhl A, Johnson J, Harshyne L, Linnenbach A, Shukla S, Alnemri A, et al.
Clin Cancer Res
. 2021 Dec;
28(5):915-927.
PMID: 34911681
Purpose: We hypothesize that the addition of the phosphodiesterase-5 inhibitor tadalafil to the PD-1 inhibitor nivolumab, is safe and will augment immune-mediated antitumor responses in previously untreated squamous cell carcinoma...
9.
Flemming J, Hill B, Anderson-Pullinger L, Harshyne L, Mahoney M
JID Innov
. 2021 Dec;
1(4):100053.
PMID: 34909749
Exosomes or small extracellular vesicles (sEVs) are membrane-bound nanoparticles that carry various macromolecules and act as autocrine and paracrine signaling messengers. In this study, sEVs from epidermoid carcinoma cells influenced...
10.
Prosniak M, Harshyne L, Gorky J, Curtis M, Kenyon L, Schwaber J, et al.
J Immunol
. 2021 Mar;
206(7):1483-1492.
PMID: 33685995
Patients with grade III anaplastic astrocytomas (AA) separate into survival cohorts based on the presence or absence of mutations in isocitrate dehydrogenase (IDH). Progression to glioblastoma (GBM), morphologically distinguishable by...